This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
by Zacks Equity Research
Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
by Zacks Equity Research
Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.
Why Atea Pharmaceuticals (AVIR) Might Surprise This Earnings Season
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.
Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
Atea (AVIR) Dengue Candidate Gets Fast Track Designation
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.
Atea Pharmaceuticals, Inc. (AVIR) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Atea Pharmaceuticals, Inc. (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Atea Pharmaceuticals, Inc. (AVIR) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Atea Pharmaceuticals, Inc. (AVIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Implied Volatility Surging for Atea (AVIR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Atea (AVIR) stock based on the movements in the options market lately.
Atea (AVIR) Plunges on Termination of Collaboration With Roche
by Zacks Equity Research
Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.
Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Atea (AVIR) Plunges on Oral COVID Candidate Study Failure
by Zacks Equity Research
Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.
Merck (MRK) Seeks Emergency Nod for Oral Antiviral COVID-19 Pill
by Zacks Equity Research
Merck's (MRK) molnupiravir to be the first oral antiviral medicine for the treatment of COVID-19, if authorized by the FDA.
RedHill (RDHL) COVID Pneumonia Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Redhill's (RDHL) opaganib achieves a significant reduction in mortality in hospitalized patients with severe COVID-19 pneumonia based on new data from the phase II/III study.
3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data
by Zacks Equity Research
Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC (Revised)
by Zacks Equity Research
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.